• Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Social icon element need JNews Essential plugin to be activated.
Tuesday, May 5, 2026
Daily The Business
  • Login
No Result
View All Result
DTB
No Result
View All Result
DTB

Import of pharma products: PCDA voices concern over new infrastructure cess

September 8, 2024
in Business & Finance
Import of pharma products: PCDA voices concern over new infrastructure cess

KARACHI: The Pakistan Chemist and Druggist Association (PCDA) has raised serious concerns over the imposition of infrastructure cess at the import stage, imposed by the Excise, Taxation & Narcotics Control Department of Sindh.

The PCDA emphasised the detrimental impact this levy has on the import of critical pharmaceutical products.

According to the spokesperson of PCDA Abdul Samad Budhani, pharmaceutical imports consist of life-saving medicines crucial for the treatment of critical diseases, including Cardiology, Oncology, Neurology, and Nephrology. Most of these medicines are not manufactured locally, making their import vital to the healthcare sector.

However, he said, due to the escalating costs associated with the infrastructure cess, many pharmaceutical companies have ceased imports, leaving patients vulnerable and worsening the availability of critical medications.

In a letter addressed to the Secretary of Excise, Taxation & Narcotics Control, Sindh, the Senior Vice President of the Federation of Pakistan Chambers of Commerce & Industry (FPCCI), Saquib Fayyaz Magoon, highlighted the urgency of the situation.

He emphasized the need for a review of the Sindh Development and Infrastructure Cess 2017, which, according to stakeholders, has made the import of finished medicines commercially unviable.

The issue was also previously raised in a letter dated February 27, 2024, but remains unresolved.

“The availability of essential imported medicines is already shrinking, causing grave concerns for patients who rely on these treatments. In the better interest of sustaining medical practices in Pakistan, it is imperative to find a solution,” Magoon stated.

The FPCCI has requested the department to hold a personal hearing with representatives from the PCDA to discuss the issue further and develop a comprehensive strategy to address the matter. The association awaits a response from the Excise Department, hoping for a timely resolution to avert a potential healthcare crisis.

This development comes at a time when the pharmaceutical industry is already grappling with supply chain disruptions and increasing production costs, making the removal or adjustment of such levies crucial to the industry’s survival.

Copyright media, 2024

Tags: PCDAPharma sectorPharmaceutical IndustryPharmaceutical products
Previous Post

TDAP invites companies to participate in ‘FoodAg Manufacturing 2024’

Next Post

Policy Board members will support govt in financial affairs: Iqbal

American Dollar Exchange Rate
Write us: info@dailythebusiness.com

© 2021 Daily The Business

Social icon element need JNews Essential plugin to be activated.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result

© 2021 Daily The Business

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Hacklink Satın Al